Published in Otol Neurotol on September 01, 2008
miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. Cancer Res (2010) 1.54
ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol (2010) 1.04
Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta Neuropathol (2011) 1.04
miRNA signature of schwannomas: possible role(s) of "tumor suppressor" miRNAs in benign tumors. Oncotarget (2011) 1.01
ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas. Otol Neurotol (2011) 0.85
Neuronal merlin influences ERBB2 receptor expression on Schwann cells through neuregulin 1 type III signalling. Brain (2013) 0.84
Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. Otol Neurotol (2010) 0.84
A neuronal function of the tumor suppressor protein merlin. Acta Neuropathol Commun (2014) 0.83
p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB. Glia (2014) 0.83
Treatment of vestibular schwannoma cells with ErbB inhibitors. Otol Neurotol (2012) 0.81
Estrogen receptor expression in sporadic vestibular schwannomas. Otol Neurotol (2011) 0.79
DNA copy gains of tumor-related genes in vestibular schwannoma. Eur Arch Otorhinolaryngol (2012) 0.77
Inhibition of c-Jun N-terminal kinase activity enhances vestibular schwannoma cell sensitivity to gamma irradiation. Neurosurgery (2013) 0.75
BAY 61-3606, CDKi, and sodium butyrate treatments alter gene expression in human vestibular schwannomas and cause cell death in vitro. Ecancermedicalscience (2012) 0.75
Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature (1993) 6.67
A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell (1993) 6.29
Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys (2004) 3.68
Neurofibromatosis 2. Curr Opin Neurol (2003) 3.46
Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev (2000) 2.72
Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev (1998) 2.66
Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer (2007) 2.20
A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J (2004) 1.85
Conservative management of acoustic neuroma: a meta-analysis and proposed treatment algorithm. Laryngoscope (2005) 1.84
High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Hum Mol Genet (2001) 1.79
Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet (2005) 1.72
Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res (2007) 1.71
Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Hum Mol Genet (2003) 1.47
Role of neuregulins in glial cell development. Glia (2000) 1.45
Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. Proc Natl Acad Sci U S A (2006) 1.35
Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci U S A (2004) 1.34
Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. Cancer Res (2007) 1.28
Report of 190 consecutive cases of large acoustic tumors (vestibular schwannoma) removed via the translabyrinthine approach. J Neurosurg (1999) 1.25
Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. Nat Genet (2002) 1.22
Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors. Oncogene (2005) 1.21
Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation. Glia (2006) 1.18
Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol (2003) 1.18
Malignancy in a vestibular schwannoma. Report of a case with central neurofibromatosis, treated by both stereotactic radiosurgery and surgical excision, with a review of the literature. Br J Neurosurg (2002) 1.17
ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy. Otol Neurotol (2008) 1.15
Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol Ther (2007) 1.15
Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res (2006) 1.12
NF2 gene in neurofibromatosis type 2 patients. Hum Mol Genet (1998) 1.11
Hypertrophic neuropathies and malignant peripheral nerve sheath tumors in transgenic mice overexpressing glial growth factor beta3 in myelinating Schwann cells. J Neurosci (2003) 1.10
Comparison of growth patterns of acoustic neuromas with and without radiosurgery. Otol Neurotol (2006) 1.07
Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects. Otol Neurotol (2004) 1.02
Universal absence of merlin, but not other ERM family members, in schwannomas. Am J Pathol (1997) 1.02
Neuregulin growth factors and their ErbB receptors form a potential signaling network for schwannoma tumorigenesis. J Neuropathol Exp Neurol (2006) 1.00
Malignant transformation of a recurrent vestibular schwannoma. J Clin Pathol (2004) 0.99
Mouse models of neurofibromatosis 1 and 2. Neoplasia (2002) 0.98
Age at symptom onset and long-term survival in patients with neurofibromatosis Type 2. J Neurosurg (2003) 0.97
Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. Hum Gene Ther (2006) 0.97
Small acoustic neuromas: surgical outcomes versus observation or radiation. Otol Neurotol (2006) 0.96
In vitro and in vivo effects of combination of Trastuzumab (Herceptin) and Tamoxifen in breast cancer. Breast Cancer Res Treat (2005) 0.95
Expression of neuregulin and activation of erbB receptors in vestibular schwannomas: possible autocrine loop stimulation. Otol Neurotol (2004) 0.93
Constitutive activation of the neuregulin-1/ErbB receptor signaling pathway is essential for the proliferation of a neoplastic Schwann cell line. Glia (2003) 0.92
The molecular biology of vestibular schwannomas: dissecting the pathogenic process at the molecular level. Otol Neurotol (2006) 0.92
Molecular studies of vestibular schwannomas: a review. Curr Opin Otolaryngol Head Neck Surg (2007) 0.90
Merlin suppresses the SRE-dependent transcription by inhibiting the activation of Ras-ERK pathway. Biochem Biophys Res Commun (2003) 0.88
The Phosphorylation status of merlin is important for regulating the Ras-ERK pathway. Mol Cells (2005) 0.88
p75NTR and sortilin increase after facial nerve injury. Laryngoscope (2008) 0.87
Growth of human acoustic neuromas, neurofibromas and schwannomas in the subrenal capsule and sciatic nerve of the nude mouse. J Neurooncol (1992) 0.87
Lipid raft localization of ErbB2 in vestibular schwannoma and schwann cells. Otol Neurotol (2008) 0.86
Merlin inhibits growth hormone-regulated Raf-ERKs pathways by binding to Grb2 protein. Biochem Biophys Res Commun (2005) 0.85
Growth of benign and malignant schwannoma xenografts in severe combined immunodeficiency mice. Laryngoscope (2006) 0.85
Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression. Anticancer Res (2006) 0.85
News on the genetics, epidemiology, medical care and translational research of Schwannomas. J Neurol (2006) 0.84
Management of acoustic neuromas in patients 65 years or older. Otol Neurotol (2007) 0.82
Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2. Neoplasia (2002) 0.82
National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma, December 11-13, 1991. The Consensus Development Panel. Arch Neurol (1994) 0.82
Expression of ErbB-1 and 2 in vestibular schwannomas. J Clin Neurosci (2007) 0.81
Phenotypic variability in two families with novel splice-site and frameshift NF2 mutations. Hum Genet (1996) 0.80
Stereotactic radiosurgery, microsurgery, and expectant management of acoustic neuroma: basis for informed consent. Otolaryngol Clin North Am (2005) 0.78
Subcutaneous growth of human acoustic schwannomas in athymic nude mice. Acta Otolaryngol (1994) 0.76
Growth of human schwannomas in the subrenal capsule of the nude mouse. Neurosurgery (1990) 0.76
Hybrid 10 clinical trial: preliminary results. Audiol Neurootol (2009) 2.20
Strategies to preserve or regenerate spiral ganglion neurons. Curr Opin Otolaryngol Head Neck Surg (2005) 1.31
Stapedectomy versus stapedotomy: comparison of results with long-term follow-up. Laryngoscope (2002) 1.12
Membrane depolarization inhibits spiral ganglion neurite growth via activation of multiple types of voltage sensitive calcium channels and calpain. Mol Cell Neurosci (2007) 1.05
Diagnosis of ear pain. Am Fam Physician (2008) 1.04
Canal wall reconstruction tympanomastoidectomy with mastoid obliteration. Laryngoscope (2005) 1.03
MicroRNA-21 overexpression contributes to vestibular schwannoma cell proliferation and survival. Otol Neurotol (2010) 0.97
Small acoustic neuromas: surgical outcomes versus observation or radiation. Otol Neurotol (2006) 0.96
Prediction of cochlear implant performance by genetic mutation: the spiral ganglion hypothesis. Hear Res (2012) 0.94
Micropatterned methacrylate polymers direct spiral ganglion neurite and Schwann cell growth. Hear Res (2011) 0.94
Barriers to the early cochlear implantation of deaf children. Otol Neurotol (2011) 0.92
Hearing Loss After Activation of Hearing Preservation Cochlear Implants Might Be Related to Afferent Cochlear Innervation Injury. Otol Neurotol (2015) 0.92
Photopolymerized microfeatures for directed spiral ganglion neurite and Schwann cell growth. Biomaterials (2012) 0.91
p75(NTR) expression and nuclear localization of p75(NTR) intracellular domain in spiral ganglion Schwann cells following deafness correlate with cell proliferation. Mol Cell Neurosci (2011) 0.89
Polymorphisms in KCNE1 or KCNE3 are not associated with Ménière disease in the Caucasian population. Am J Med Genet A (2010) 0.89
Overexpression of Bcl-2 or Bcl-xL prevents spiral ganglion neuron death and inhibits neurite growth. Dev Neurobiol (2007) 0.88
Risk factors for loss of ipsilateral residual hearing after hybrid cochlear implantation. Otol Neurotol (2014) 0.88
p75NTR and sortilin increase after facial nerve injury. Laryngoscope (2008) 0.87
Contribution of persistent C-Jun N-terminal kinase activity to the survival of human vestibular schwannoma cells by suppression of accumulation of mitochondrial superoxides. Neuro Oncol (2011) 0.87
The Coxsackievirus and Adenovirus Receptor: a new adhesion protein in cochlear development. Hear Res (2006) 0.87
Lipid raft localization of ErbB2 in vestibular schwannoma and schwann cells. Otol Neurotol (2008) 0.86
Interaction of neurotrophin signaling with Bcl-2 localized to the mitochondria and endoplasmic reticulum on spiral ganglion neuron survival and neurite growth. J Neurosci Res (2010) 0.85
Neural pathfinding on uni- and multidirectional photopolymerized micropatterns. ACS Appl Mater Interfaces (2014) 0.85
Influence of cAMP and protein kinase A on neurite length from spiral ganglion neurons. Hear Res (2011) 0.84
Activity of all JNK isoforms contributes to neurite growth in spiral ganglion neurons. Hear Res (2011) 0.83
Material stiffness effects on neurite alignment to photopolymerized micropatterns. Biomacromolecules (2014) 0.83
p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB. Glia (2014) 0.83
Neurolymphomatosis mimicking chemotherapy-induced ototoxicity. Otol Neurotol (2009) 0.82
Subtotal petrosectomy and mastoid obliteration in adult and pediatric cochlear implant recipients. Otol Neurotol (2013) 0.81
Cochlear implantation and single-sided deafness. Curr Opin Otolaryngol Head Neck Surg (2014) 0.81
Regulation of 14-3-3sigma expression in human thyroid carcinoma is epigenetically regulated by aberrant cytosine methylation. Cancer Lett (2008) 0.81
Middle ear cancer: a population-based study. Laryngoscope (2009) 0.81
Resident participation in cadaveric temporal bone dissection correlates with improved performance on a standardized skill assessment instrument. Otol Neurotol (2014) 0.81
Facial Nerve Outcome and Tumor Control Rate as a Function of Degree of Resection in Treatment of Large Acoustic Neuromas: Preliminary Report of the Acoustic Neuroma Subtotal Resection Study (ANSRS). Neurosurgery (2016) 0.80
Facial and lower cranial neuropathies after preoperative embolization of jugular foramen lesions with ethylene vinyl alcohol. Otol Neurotol (2012) 0.80
Zinc to treat tinnitus in the elderly: a randomized placebo controlled crossover trial. Otol Neurotol (2013) 0.80
In vivo examination of meibomian gland morphology in patients with facial nerve palsy using infrared meibography. Ophthal Plast Reconstr Surg (2012) 0.79
Mouse cochleostomy: a minimally invasive dorsal approach for modeling cochlear implantation. Laryngoscope (2013) 0.79
The rising incidence of spontaneous cerebrospinal fluid leaks in the United States and the association with obesity and obstructive sleep apnea. Otol Neurotol (2015) 0.79
Bicarbonate disruption of the pulmonary endothelial barrier via activation of endogenous soluble adenylyl cyclase, isoform 10. Am J Physiol Lung Cell Mol Physiol (2013) 0.78
Long-term results of canal wall reconstruction tympanomastoidectomy. Otol Neurotol (2014) 0.78
Long-term results of canal wall reconstruction tympanomastoidectomy. Otol Neurotol (2014) 0.77
Ganglion cyst presenting as an external auditory canal mass. Otolaryngol Head Neck Surg (2011) 0.77
Is electroneurography beneficial in the management of Bell's palsy? Laryngoscope (2013) 0.76
A Series of Case Studies of Tinnitus Suppression With Mixed Background Stimuli in a Cochlear Implant. Am J Audiol (2015) 0.76
Functional variants in NOS1 and NOS2A are not associated with progressive hearing loss in Ménière's disease in a European Caucasian population. DNA Cell Biol (2011) 0.76
Radiographic association of schwannomas with sensory ganglia. Otol Neurotol (2012) 0.76
Repair of posterior semicircular canal dehiscence from a high jugular bulb. Ann Otol Rhinol Laryngol (2013) 0.75
Inhibition of c-Jun N-terminal kinase activity enhances vestibular schwannoma cell sensitivity to gamma irradiation. Neurosurgery (2013) 0.75
Vestibular Schwannomas: Do Linear and Volumetric Parameters on MRI Correlate With Hearing Loss? Otol Neurotol (2016) 0.75
Calculating the Tumor Volumes in Vestibular Schwannomas: Are the ABC/2 and Volumetric Methods Comparable? Otol Neurotol (2017) 0.75
Acute radiographic workup of blunt temporal bone trauma: maxillofacial versus temporal bone CT. Laryngoscope (2009) 0.75
Development of a preliminary pediatric tracheal growth model from magnetic resonance images. Laryngoscope (2014) 0.75
Retrograde labeling of the rat facial nerve with carbocyanine dyes to enhance intraoperative identification. Ann Otol Rhinol Laryngol (2008) 0.75
Disseminated histoplasmosis presenting as a unilateral cranial nerve VIII mass: a case report. Otol Neurotol (2006) 0.75
Cavernous hemangioma of the endolymphatic sac. Otol Neurotol (2006) 0.75
Treatment of Lateral Skull Base and Posterior Cranial Fossa Lesions Utilizing the Extended Middle Cranial Fossa Approach. Otol Neurotol (2017) 0.75
Calvarium thinning in patients with spontaneous cerebrospinal fluid leak. Otol Neurotol (2015) 0.75
Zygomatic root abscess: a rare complication of otitis media. Otol Neurotol (2010) 0.75
Reconstruction Outcomes Following Lateral Skull Base Resection. Otol Neurotol (2016) 0.75
Methicillin-Resistant Staphylococcus aureus Otic Capsule and Pontine Infection Masquerading as an Internal Auditory Canal Neoplasm. Otol Neurotol (2015) 0.75
Optically guided stereotactic radiotherapy for facial nerve paralysis secondary to occult malignant neoplasms. Otolaryngol Head Neck Surg (2006) 0.75
Cerebral venous sinus thrombosis following jugular bulb decompression. Semin Ophthalmol (2006) 0.75
Middle Cranial Fossa (MCF) Approach Without the Use of Lumbar Drain for the Management of Spontaneous Cerebral Spinal Fluid (CSF) Leaks. Otol Neurotol (2016) 0.75